Dilipkumar Patel, MD
Retina Specialist · Buffalo, NYNPI 1437177425
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,574 and has fallen 71.5% since, to $449 in 2025.
Across 98 payments — averaging $43.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$988
- AbbVie$882
- Bausch & Lomb Americas Inc.$564
- Aerie Pharmaceuticals, Inc.$337
- Alcon$275
- Sun Pharmaceutical Industries Inc.$205
- plus $991 from 10 others
Across 13 payments — averaging $6620.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$86K
What the payments were for
- Food & beverage$4,224100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 8 | $988 |
| AbbVie(2 entities) | 27 | $882 |
| Bausch & Lomb Americas Inc. | 8 | $564 |
| Aerie Pharmaceuticals, Inc. | 14 | $337 |
| Alcon | 10 | $275 |
| Sun Pharmaceutical Industries Inc. | 10 | $205 |
| Carl Zeiss Meditec, Inc. | 2 | $178 |
| ANI Pharmaceuticals, Inc. | 1 | $125 |
| Apellis Pharmaceuticals, Inc. | 1 | $116 |
| Alimera Sciences, Inc. | 2 | $106 |
| Sight Sciences, Inc. | 1 | $105 |
| Astellas Pharma US Inc | 4 | $97 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $95 |
| Novartis | 5 | $85 |
| Oyster Point Pharma, Inc. | 3 | $61 |
| Daiichi Sankyo Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,242 in reported general payments places this provider in the 65th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 174 | $117,258 |
| RestasisCyclosporine | 39 | $60,724 |
| Cyclosporine | 56 | $38,819 |
| RhopressaNetarsudil Mesylate | 60 | $30,210 |
| XiidraLifitegrast | 22 | $29,796 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 74 | $21,799 |
| Travoprost | 63 | $17,822 |
| Restasis MultidoseCyclosporine | 13 | $17,793 |
| Latanoprost | 665 | $14,849 |
| Brimonidine Tartrate | 60 | $9,392 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $6,753 |
| Timolol Maleate | 219 | $5,244 |
| ProlensaBromfenac Sodium | 13 | $4,680 |
| Ketorolac Tromethamine | 29 | $2,292 |
| Pilocarpine Hcl | 25 | $2,189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Restasis Multidose, Combigan | $882 | $202,527242 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $337 | $30,21060 claims |
| Bausch & Lomb Americas Inc.Xiidra | $564 | $29,79622 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $95 | $4,68013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 99 retina specialist providers in New York.
Other retina specialist in Buffalo
- Paul HahnNanuet$238K
- Deepika MalikWoodbury$221K
- Szilard KissNew York$195K
- Ferhina AliValhalla$176K
- Donald D'amicoNew York$109K
- Matthew WitmerRochester$62K
- Avnish DeobhaktaBrooklyn$46K
- Edward HallRochester$38K
- Philip NilesWilliamsville$30K
- Mark BreazzanoLiverpool$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.